US · Healthcare · Biotechnology
EPS came in at -1.23 against a street estimate of -1.20 — a miss of 2.5%.
Analysts rate Crinetics Pharmaceuticals Inc a strong buy (16 buy, 1 hold, 0 sell out of 17) with an average price target of $85.50.
| Fund | Stake |
|---|---|
| FMR Inc | 14.89% |
| BlackRock Inc | 8.01% |
| Farallon Capital Management, L.L.C. | 7.88% |
| Wellington Management Company LLP | 7.71% |
| Driehaus Capital Management LLC | 6.04% |
| T. Rowe Price Associates, Inc. | 5.06% |
| Vanguard Capital Management, LLC | 4.42% |
| Vanguard Portfolio Management, LLC | 4.38% |
| Document | Date |
|---|---|
| Material agreement · Q3 2026 | 2026-07-10 |
| Material agreement · Q3 2026 | 2026-07-06 |
| Shareholder vote results · Q2 2026 | 2026-06-22 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-29 |
| Annual report FY2025 | 2026-02-26 |
| Quarterly report · Q3 2025 | 2025-11-06 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Crinetics Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.